



Syndax Announces Clinical Data from its Entinostat Immuno-oncology Program Selected for Two Oral Presentations at the American Association for Cancer Research Annual Meeting 2019

February 27, 2019

WALTHAM, Mass., Feb. 27, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced two oral presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting being held March 29 - April 3, 2019 in Atlanta, Georgia.

Oral Presentation Details

Title: [Identification of gene signatures associated with response in a Phase 2 trial of entinostat \(ENT\) plus pembrolizumab \(PEMBRO\) in non-small cell lung cancer \(NSCLC\) patients whose disease has progressed on or after anti-PD-\(L\)1 therapy](#)

First author: Peter Ordentlich, Ph.D.

Session: Advances in Novel Immunotherapeutics (Clinical Trials Minisymposium)

Abstract Number: 7822

Location: Georgia World Congress Center, Building A, Room 411

Date and Time: Sunday, March 31, 2019; 3:00 p.m. - 5:00 p.m. ET

Title: [Efficacy and safety of entinostat \(ENT\) and pembrolizumab \(PEMBRO\) in patients with melanoma previously treated with anti-PD1 therapy](#)

First author: Ryan Sullivan, M.D.

Session: Optimizing PD-1/PD-L1 Immune Checkpoint Inhibitor Therapy (Clinical Trials Plenary Session)

Abstract Number: 7449

Location: Georgia World Congress Center, Building A, Marcus Auditorium

Date and Time: Monday, April 1, 2019; 10:30 a.m. - 12:30 p.m. ET

All accepted abstracts will be published in the 2019 *Proceedings of the AACR*. Session information is available online via the Annual Meeting Itinerary Planner through the AACR website at www.aacr.org.

About Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. The Company is developing its lead product candidate, entinostat, a once-weekly, oral, small molecule, class I HDAC inhibitor, in combination with exemestane and several approved PD-1/PD-(L)1 antagonists. The Company's pipeline also includes SNDX-6352, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor, as well as a portfolio of potent and selective inhibitors targeting the binding interaction of Menin with MLL-r, including its lead candidate SNDX-5613. For more information, please visit www.syndax.com or follow the Company on [Twitter](#) and [LinkedIn](#).

Syndax's Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend," "believe" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Syndax's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the progress, timing, clinical development and scope of clinical trials and the reporting of clinical data for Syndax's product candidates, and the potential use of our product candidates to treat various cancer indications. Many factors may cause differences between current expectations and actual results including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, failure of Syndax's collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes. Other factors that may cause Syndax's actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Syndax's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, Syndax assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Syndax Contacts

Investor Contact

Melissa Forst

Argot Partners

melissa@argotpartners.com

Tel 212.600.1902

Media Contact


David Rosen

Argot Partners

david.rosen@argotpartners.com

Tel 212.600.1902

SNDX-G

 View original content: <http://www.prnewswire.com/news-releases/syndax-announces-clinical-data-from-its-entinostat-immuno-oncology-program-selected-for-two-oral-presentations-at-the-american-association-for-cancer-research-annual-meeting-2019-300803642.html>

SOURCE Syndax Pharmaceuticals, Inc.